Lv11
98 积分 2023-12-19 加入
JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options
5天前
已完结
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
6天前
已完结
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
6天前
已完结
Pacritinib: First Approval
6天前
已完结
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
6天前
已完结
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
6天前
已完结
Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis
6天前
已关闭
Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer
16天前
已完结
Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519–25
16天前
已完结
A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
20天前
已完结
皖公网安备34019202002308
